Who founded ORIC Pharmaceuticals?

ORIC Pharmaceuticals was founded by Richard Heyman, Charles Sawyers, Scott Lowe in 2014.

Who are ORIC Pharmaceuticals's investors?

ORIC Pharmaceuticals's investors include EcoR1 Capital, New Enterprise Associates (NEA), Nextech Invest, Taiho Ventures, LLC, The Column Group, Viking Global, OrbiMed.

How much funding has ORIC Pharmaceuticals raised?

ORIC Pharmaceuticals has disclosed $335M raised across 3 rounds.

Where is ORIC Pharmaceuticals headquartered?

ORIC Pharmaceuticals is headquartered in South San Francisco, US.

ORIC Pharmaceuticals

NASDAQ: ORIC

South San Francisco, US · Founded 2014 · Delaware corporation · 138 employees on LinkedIn · 7 known investors

Find your way into ORIC Pharmaceuticals

Paths you didn't know you had: your email and LinkedIn already hold routes to the ORIC Pharmaceuticals team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance. Its pipeline includes rinzimetostat (ORIC-944) in Phase 1b for prostate cancer and enozertinib (ORIC-114) in Phase 1b for non-small cell lung cancer with EGFR mutations.

Biotech Healthtech

Founders & leadership

ORIC Pharmaceuticals was founded in 2014 by Richard Heyman, Charles Sawyers, and Scott Lowe.

Richard Heyman Co-founder · Chairman of the BODVenture Partner at ARCH Venture Partners

Charles SawyersFounder, Scientific Advisory BoardScience Partner at Nextech Invest

Scott LoweFounder, Scientific Advisory Board

Dominic PiscitelliChief Financial Officer

Pratik Multani Chief Medical OfficerPratik Multani is a medical oncologist with experience across the drug development lifecycle, including regulatory submissions, clinical trial design and execution, and FDA interactions. He has led cross-functional teams and brings expertise in strategic planning, trial execution, and stakeholder communication in oncology.

Jacob ChackoPresident, Chief Executive Officer and Board Member

Kevin Brodbeck Chief Technical OfficerKevin Brodbeck holds a Ph.D. in chemical engineering from UC Berkeley and the University of Illinois Urbana-Champaign. He spent nine years at Nektar Therapeutics leading CMC development across oncology, immunotherapy, and other therapeutic areas, and previously held roles in product development at ALZA/Johnson & Johnson (where he led development of the Viadur leuprolide implant and the Injectable Depot platform) and as head of biopharmaceutical formulation at Powderject.

Lori FriedmanChief Scientific Officer

Matthew PanuwatChief Business Officer

Christian V. KuhlenGeneral Counsel

Board

Steve L. HoerterMember Board of DirectorsChairman & Chief Executive Officer at MBX Biosciences

Lori KunkelBoard director

Investors · 7

EcoR1 Capitallisted by EcoR1 CapitalSan Francisco

How we know: the S-1 prospectus · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · Not right? Tell us

Taiho Ventures, LLClisted by Taiho Ventures, LLCMenlo Park

The Column Grouplisted by The Column GroupSan Francisco · $30M

How we know: The Column Group's portfolio page · Not right? Tell us

Viking Globallisted by Viking GlobalStamford

How we know: Viking Global's portfolio page · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$335M disclosed across 3 rounds · 2023–2025

▶$125MraisedJun 2025 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steve L. HoerterDirector
Lori KunkelDirector
Jacob M. ChackoExecutive Officer, Director
Richard HeymanDirector
Dominic PiscitelliExecutive Officer
Angie YouDirector
Pratik MultaniExecutive Officer
Mardi C. DierDirector

Offering amount: $125M
Amount sold: $125M
First sale: May 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$125MraisedJan 2024 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Angie YouDirector
Lori KunkelDirector
Steve L. HoerterDirector
Dominic PiscitelliExecutive Officer
Jacob M. ChackoExecutive Officer, Director
Richard HeymanDirector
Mardi DierDirector
Pratik MultaniExecutive Officer

Offering amount: $125M
Amount sold: $125M
First sale: Jan 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$85MraisedJul 2023 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Angie YouDirector
Richard HeymanDirector
Steve L. HoerterDirector
Jacob M. ChackoExecutive Officer, Director
Mardi DierDirector
Lori KunkelDirector
Dominic PiscitelliExecutive Officer
Pratik MultaniExecutive Officer

Offering amount: $85M
Amount sold: $85M
First sale: Jun 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$818.6Mvaluation at IPONov 2020 · $23.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through ORIC Pharmaceuticals went on to found or lead other companies.

Richard HeymanChairman, Founder, Scientific Advisory BoardFounded Aragon Pharmaceuticals +2 Angie YouDirectorFounded Amunix Pharmaceuticals +1

Related companies · 3

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies working in the same space as ORIC Pharmaceuticals.

In the news

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - ORIC Pharmaceuticalsoricpharma.com · Aug 2026

Frequently asked questions

What does ORIC Pharmaceuticals do?: ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance. Its pipeline includes rinzimetostat (ORIC-944) in Phase 1b for prostate cancer and enozertinib (ORIC-114) in Phase 1b for non-small cell lung cancer with EGFR mutations.
Who founded ORIC Pharmaceuticals?: ORIC Pharmaceuticals was founded by Richard Heyman, Charles Sawyers, Scott Lowe in 2014.
Who are ORIC Pharmaceuticals's investors?: ORIC Pharmaceuticals's investors include EcoR1 Capital, New Enterprise Associates (NEA), Nextech Invest, Taiho Ventures, LLC, The Column Group, Viking Global, OrbiMed.
How much funding has ORIC Pharmaceuticals raised?: ORIC Pharmaceuticals has disclosed $335M raised across 3 rounds.
Where is ORIC Pharmaceuticals headquartered?: ORIC Pharmaceuticals is headquartered in South San Francisco, US.